Second Revision News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Second revision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Second Revision Today - Breaking & Trending Today

DRINKING WATER QUALITY STANDARDS AND IMPLEMENTATION

Safe drinking-water is a human right. Through Sustainable Development Goal 6 – to ensure availability and sustainable management of water and sanitation for all by 2030 – the world reaffirmed its commitment to ensure safe drinking-water for all.

Inadequate management of urban, industrial and ....

Management Foundation , Ministry Of Rural Development , Ministry Of Jal Shakti , Agriculture Division Council , Community Management , Sustainable Development Goal , Central Water Commission , National Environmental Engineering Research Institute , Drinking Water Sectional Committee , National Accreditation Board For Testing , Jal Ministry , Institution Of Public Health Engineers , Jal Shakti , Rural Development , Second Revision , Indian Standard , Public Health Engineers , Natural Resource Economics , Water Sectional Committee , Drinking Water Quality , Operational Monitoring , Accreditation Board , Calibration Laboratories , Accredited Testing Laboratories , Water Safety Plan , Stipulate Minimum ,

New Multiple Myeloma Staging Systems Outperform the Standard

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages. ....

United States , Salt Lake City , University Of Utah , Manni Mohyuddin , Flatiron Health , Huntsman Cancer Institute , American Society Of Hematology , International Staging System , American Society , Revised International Staging System , Second Revision , Mayo Additive Staging System , Salt Lake , Medscape Medical , Multiple Myeloma , Plasma Cell Myeloma , Alignant Neoplasia , Alignant Neoplasm , Clinical Research , Clinical Trials , Linical Studies , Pre Clinical Trial , Double Blind Study , Double Blind Studies , Ingle Blind Study , Ingle Blind Studies ,

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma. ....

Azienda Ospedaliero Universitaria Citt , University Of Torino , Health Sciences , Second Revision Of International Staging System , Department Of Molecular Biotechnology , International Staging System , International Myeloma Working Group , Molecular Biotechnology , Second Revision , Revised International Staging System , Isa Krd , Iskia Trial , Mrd Negativity Rates , Newly Diagnosed Multiple Myeloma ,

Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd

Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status. ....

United States , Nordrhein Westfalen , Dana Farber Cancer Institute , Lisa Leypoldt , University Medical Center Hamburg , International Myeloma Society Annual Meeting , Harvard Medical School , Myeloma Society Annual Meeting , University Medical Center Hamburg Eppendorf , Second Revision ,

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status. ....

Dana Farber Cancer Institute , United States , Nordrhein Westfalen , Lisa Leypoldt , Department Of Medicine At Harvard Medical School , Bristol Myers Squibb , University Medical Center Hamburg , International Staging Score , International Myeloma Society Annual Meeting , Myeloma Society Annual Meeting , University Medical Center Hamburg Eppendorf , Medical Oncology , Harvard Medical School , Second Revision , Nd Dexamethasone , Patients With Newly Diagnosed , High Risk Multiple Myeloma , Gmmg Concept Trial ,